How should a nephrologist manage a 75‑kg adult with hypertension (blood pressure 140/90 mmHg, pulse 85/min), a history of conservatively treated renal calculi, hypertensive epistaxis, a recent urinary‑tract infection, and fluctuating serum creatinine of 1.2–1.6 mg/dL who is currently taking low‑dose aspirin 75 mg daily and CILACAR‑T (calcium‑channel blocker)?

Nephrologic Management of CKD with Hypertension and Fluctuating Creatinine

Add an ACE inhibitor or ARB immediately to this patient's regimen, targeting blood pressure <130/80 mmHg, and check urine albumin-to-creatinine ratio within the next week to guide renoprotective therapy intensity. 1, 2, 3

Immediate Diagnostic Priorities

Quantify albuminuria urgently with a spot urine albumin-to-creatinine ratio (UACR)—this single test determines whether you initiate RAS blockade and predicts CKD progression risk. 1 The creatinine fluctuation from 1.2 to 1.6 mg/dL (estimated GFR approximately 45–60 mL/min/1.73 m² for a 75-kg adult) places this patient in CKD stage G3a–G3b, where albuminuria status completely changes management. 1, 2

Obtain a renal ultrasound to exclude obstructive uropathy from recurrent nephrolithiasis, assess kidney size and cortical thickness, and rule out structural abnormalities that might explain the renal dysfunction. 4, 5

Measure serum potassium, bicarbonate, and calculate eGFR using the CKD-EPI equation before starting any RAS blocker. 1

Blood Pressure Management

Target Blood Pressure

Aim for office BP <130/80 mmHg—the 2023 ESH Guidelines (endorsed by the European Renal Association) recommend this target for CKD patients, explicitly advising against pushing below 120/70 mmHg in all patients. 2, 3 The current BP of 140/90 mmHg requires intensification.

Antihypertensive Regimen

Replace CILACAR-T (cilnidipine + telmisartan) with a higher-dose ARB or add an ACE inhibitor if the current telmisartan dose is subtherapeutic. 1, 4 If UACR returns ≥300 mg/g (severely increased albuminuria, A3), ACE inhibitor or ARB therapy becomes a strong recommendation regardless of diabetes status. 1 If UACR is 30–299 mg/g (moderately increased, A2) without diabetes, ACE inhibitor/ARB is still reasonable for hypertension control and potential renoprotection. 1

Add chlorthalidone 12.5–25 mg daily as second-line therapy if BP remains ≥130/80 mmHg on optimized RAS blockade. 4, 2 Chlorthalidone is superior to hydrochlorothiazide in CKD and remains effective even at eGFR 30–45 mL/min/1.73 m² (the CLICK trial demonstrated efficacy in stage 4 CKD). 4 Thiazide-like diuretics address the fundamental sodium retention that drives hypertension in CKD. 6

Do NOT combine an ACE inhibitor with an ARB—dual RAS blockade increases hyperkalemia and acute kidney injury without cardiovascular or renal benefit. 1, 7

Monitoring After RAS Blocker Initiation

Check serum creatinine and potassium 2–4 weeks after starting or up-titrating the ACE inhibitor/ARB. 1 An increase in creatinine up to 30% reflects the intended hemodynamic effect (reduced intraglomerular pressure) and predicts long-term renoprotection—continue the drug unless creatinine rises >30% within 4 weeks. 1 This is a critical pitfall: clinicians often discontinue RAS blockers prematurely when creatinine rises 0.2–0.3 mg/dL, mistaking therapeutic effect for acute kidney injury. 1

Repeat potassium monitoring every 3–6 months once stable, more frequently if potassium >4.5 mEq/L or eGFR <45 mL/min/1.73 m². 1

Aspirin Continuation

Continue aspirin 75 mg daily for cardiovascular risk reduction in this patient with hypertension and probable CKD. 7 However, avoid NSAIDs entirely—they blunt RAS blockade efficacy, increase hyperkalemia risk, and can precipitate acute-on-chronic kidney injury. 1, 8 Counsel the patient to avoid over-the-counter ibuprofen or naproxen for any reason, including renal colic recurrence. 8

Nephrolithiasis Considerations

Obtain 24-hour urine collection for stone risk profile (calcium, oxalate, citrate, uric acid, volume) if not previously done, especially given the family history of pediatric nephrolithiasis in two children. 4 This raises concern for hereditary metabolic stone disease (e.g., hypercalciuria, cystinuria, primary hyperoxaluria). 4

Counsel aggressive hydration (target urine output >2 L/day) and dietary sodium restriction (<2 g/day), which simultaneously reduces stone recurrence and improves BP control. 4, 5

Resistant Hypertension Strategy

If BP remains ≥130/80 mmHg on triple therapy (RAS blocker + calcium channel blocker + chlorthalidone), add spironolactone 25 mg daily provided eGFR ≥30 mL/min/1.73 m² and potassium <4.5 mEq/L. 4, 2, 3 Check potassium within 1 week after starting spironolactone, then every 2–4 weeks until stable. 4

If eGFR falls below 30 mL/min/1.73 m² and hypertension remains uncontrolled, escalate chlorthalidone to 25 mg daily rather than adding spironolactone, due to prohibitive hyperkalemia risk. 4, 2

Follow-Up Timeline

• Week 1: UACR, serum potassium, bicarbonate, renal ultrasound, 24-hour urine stone profile
• Week 2–4: Repeat creatinine and potassium after RAS blocker initiation/titration 1
• Month 3: Reassess BP control, repeat UACR to confirm response to RAS blockade, adjust antihypertensive regimen 4, 2
• Every 3–6 months: Monitor eGFR, potassium, UACR, and BP 1, 3

Critical Pitfalls to Avoid

Do not stop the RAS blocker if creatinine rises ≤30%—this hemodynamic effect is therapeutic, not harmful. 1 Only discontinue if creatinine rises >30% within 4 weeks, or if symptomatic hypotension or refractory hyperkalemia (>5.5 mEq/L despite management) develops. 1

Do not use NSAIDs for renal colic in this CKD patient—they antagonize RAS blockade and worsen kidney function. 1, 8 Use opioids or acetaminophen for breakthrough pain if stones recur. 8

Do not target BP <120/70 mmHg—overly aggressive lowering increases adverse events without additional renal or cardiovascular benefit in CKD. 2, 3